Role of PAR-4 in ovarian cancer

Sonia Meynier; Marianne Kramer; Pascale Ribaux; Jean Christophe Tille; Florence Delie; Patrick Petignat; Marie Cohen

doi:10.18632/oncotarget.4010

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Role of PAR-4 in ovarian cancer

Sonia Meynier _, Marianne Kramer, Pascale Ribaux, Jean Christophe Tille, Florence Delie, Patrick Petignat and Marie Cohen

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:22641-22652. https://doi.org/10.18632/oncotarget.4010

Metrics: PDF 1576 views | HTML 1948 views | ?

Abstract

Sonia Meynier1, Marianne Kramer1, Pascale Ribaux1, Jean-Christophe Tille2, Florence Delie3, Patrick Petignat1, Marie Cohen1

1Department of Gynecology Obstetrics, Faculty of Medicine, University of Geneva, Switzerland

2Division of Clinical Pathology, Geneva University Hospital, University of Geneva, Switzerland

3School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Switzerland

Correspondence to:

Marie Cohen, e-mail: [email protected]

Keywords: PAR-4, GRP78, ovarian cancer, apoptosis

Received: January 13, 2015 Accepted: May 14, 2015 Published: May 27, 2015

ABSTRACT

Prostate apoptosis response-4 (PAR-4) is considered as a tumour suppressor due to its ability to selectively induce cell apoptosis in most cancer cells. However little is known about the role of PAR-4 in ovarian cancer. In this study, we investigated for the first time the role of PAR-4 in ovarian carcinogenesis. We showed that PAR-4 mRNA level is not significantly different between healthy and cancer ovarian cells. Immunohistochemistry on ovarian tissue showed that ovarian cancer cells are positive for PAR-4 nuclear and cytoplasmic staining whereas ovarian healthy cells are negative for PAR-4 nuclear staining. We then studied the role of PAR-4 in cell apoptosis. We determined that PAR-4 induces cell apoptosis in response to stimuli, in vitro, but is also involved in the relocation of GRP78 from endoplasmic reticulum to the cell surface of ovarian cancer cell line (SKOV-3 cells). In ovo, PAR-4 decreases ovarian tumour development and increases the response to taxol treatment. These observations suggest that PAR-4 is a very interesting therapeutic target against ovarian carcinogenesis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4010

Publication Alerts

Research Papers:

Role of PAR-4 in ovarian cancer

Abstract